Avextra

What Avextra does

Avextra is a vertically integrated German pharmaceutical company that develops, manufactures, and distributes cannabis-based prescription medicines across Europe. Founded in 2019 as Eurox Group and rebranded to Avextra in 2022, the company controls the entire value chain from proprietary cannabis cultivar breeding at its Avextra Portugal facility through EU-GMP certified pharmaceutical manufacturing at a 10,000 m² facility in Bensheim, Hesse, Germany. Its core product portfolio includes standardized full-spectrum cannabis extracts with defined THC/CBD profiles (notably the 10/10 formulation), Dronabinol concentrates, CBD products, and a novel oral capsule launched in December 2025. The company serves patients with chronic pain, neurodegenerative diseases, oncology-related symptoms, sleep disorders, and palliative care needs, with its products dispensed through pharmacies and medical wholesalers and reimbursable under German statutory health insurance following physician prescription and prior authorization.

Avextra underpins its commercial offering with a substantial clinical evidence program, currently running six studies including the Phase II NEUROBIS trial in Italy (180 patients across ALS, Parkinson's, and Alzheimer's, funded by the Italian Ministry of Health), the OCEAN study (~400 chemotherapy-induced neuropathic pain patients across 20+ DGS centers in Germany), the SATURN study (~400 pain patients), the IMPACT study (sleep quality), the CORAL study (palliative care), and the BELCANTO Phase II oncology study. Go-to-market relies on enterprise field sales targeting physicians and pharmacists, event-driven engagement at medical congresses (e.g., German Pain and Palliative Conference), and partnerships with medical societies such as the German Society for Pain Medicine (DGS). The Avextra Alliance for Evidence-Based Cannabis Medicine, the DocCheck-verified expert portal, and R&D collaborations with CESPU and J.W. Goethe University Frankfurt support physician adoption and indication expansion.

Revenue is generated primarily through one-time prescription sales of cannabis-based medicines and supporting pharmacy compounding relationships. Avextra has raised €37 million+ in dilutive and convertible capital across a March 2023 €17M convertible loan note and a February 2024 follow-on round of over €20M that brought post-money valuation to €100 million, supplemented by approximately $6.8M in EU non-dilutive funding in December 2024. The company employs 51–100 staff across offices in Berlin (headquarters), Bensheim (manufacturing), and Lisbon (cultivation and breeding), with operational reach extending to Germany, Portugal, the UK, and Italy.

Name

Avextra

Legal name

Avextra Pharma GmbH

Website

https://avextra.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Avextra is a vertically integrated German pharmaceutical company that develops and manufactures EU-GMP certified cannabis-based prescription medicines for chronic pain, neurodegenerative, oncology-supportive, and palliative care patients across Germany and continental Europe.

Ownership category

akta.pro rank

Headquarters

HQ city

Bensheim

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Prescription Cannabis Medicines: Avextra manufactures and sells standardized cannabis-based prescription medicines to pharmacies and healthcare providers. Products include full-spectrum extracts, capsules, and Dronabinol preparations. Distribution occurs through pharmacies and medical wholesalers in Germany and across European markets. Sales are prescription-only, requiring physician authorization.
2. Pharmacy Compounding Support: Products support pharmacy compounding operations, including Dronabinol concentrates that optimize formulation preparation in pharmacies. This creates ongoing procurement relationships with dispensing pharmacies.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Avextra is a vertically integrated German pharmaceutical company that develops, manufactures, and distributes cannabis-based prescription medicines. Its portfolio includes standardized full-spectrum cannabis extracts with defined THC and CBD profiles, novel pharmaceutical Avextra capsules, Dronabinol concentrates, and CBD products, produced at an EU-GMP certified 10,000 m² facility in Bensheim, Germany. The company controls the value chain from proprietary cannabis cultivation in Portugal through EU-GMP pharmaceutical manufacturing, supported by an ongoing clinical research program across multiple therapeutic indications.

Product overview

Avextra is a vertically integrated German biotech company specializing in the development and production of cannabis-based prescription medicines. The company controls the entire value chain from cannabis cultivation in Portugal to EU-GMP certified pharmaceutical manufacturing in Germany. The core product portfolio includes standardized cannabis extracts with defined THC and CBD profiles, novel pharmaceutical capsules (launched December 2025), and Dronabinol products. Avextra's offering is characterized by evidence-based clinical development, with six ongoing clinical studies in Germany and Europe focused on pain management, palliative care, oncology support, and neurodegenerative diseases. The company operates a 10,000 m² production facility in Bensheim, Hesse, Germany, producing pharmaceutical-grade cannabis medicines for the European market.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Nearly 400 pain patients showed significant improvements in quality of life and symptom reduction in the SATURN study
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• NEUROBIS Study (Italy)coreStrategic or Co-development Partner · 24 October 2025Phase II randomized double-blind placebo-controlled clinical trial in Italy for neurodegenerative diseases (ALS, Parkinson's, Alzheimer's). 180 patients. Funded by Italian Ministry of Health. Led by Professor Letizia Mazzini at ALS Center in Novara.
• OCEAN Study Partnership (DGS)coreStrategic or Co-development Partner · 23 January 2024Real-world observational study on chemotherapy-induced neuropathic pain (CINP) involving approximately 400 patients across over 20 DGS centers. Avextra provides cannabis extract 10/10 for evaluation under everyday treatment conditions.
• BELCANTO Clinical Trial PartnershipcoreStrategic or Co-development Partner · 18 October 2023First Avextra-supported clinical study for oncology patients. Multicenter interventional Phase II study in supportive care for oncology patients addressing high unmet medical needs. Part of Avextra Alliance for Evidence-Based Cannabis Medicine.
• CESPU (Cooperativa de Ensino Superior Politécnico e Universitário)coreStrategic or Co-development PartnerLeading Portuguese institute in pharmacy and toxicology. R&D cooperation partner for Avextra Portugal's breeding program. Collaborates on basic toxicology research and botanical starting material development for future drug formulations.
• J.W. Goethe University FrankfurtcoreStrategic or Co-development PartnerPreclinical research collaboration to better tailor cannabis-based product compositions to specific medical indications. Scientific findings will contribute to evidence-based patient care.
• DGS (Deutsche Gesellschaft für Schmerzmedizin e.V.)coreStrategic or Co-development PartnerLeading German pain medicine society with approximately 4,000 members and 120 pain centers. Partnership on OCEAN study for chemotherapy-induced neuropathic pain and DGS Cannabis Initiative 2022/23 for improving patient access to cannabis-based medicines.
• IPS PHARMAcoreChannel Partner/ Reseller/ DistributorJoint operation of Integro Medical Cannabis Clinics in Great Britain. Clinic meets highest quality standards and primarily treats patients with severe pain symptoms.
• Canopy Growth Germany GmbHminorChannel Partner/ Reseller/ DistributorDistribution partnership in certain regions. Joint responsibility arrangement for data transmission and customer contact in sales operations.
• Copeia GmbHminorImplementation/ SI/ Consulting PartnerJoint data controllers for cost coverage application support services. Copeia provides the application platform for patients seeking health insurance coverage for Avextra products.
• VCA (Verband der Cannabis versorgenden Apotheken e.V.)minorOthersProfessional association for pharmacies supplying cannabis in Germany. Promotes competence development, continuing education, and content exchange between pharmacists, industry, science and politics.
• BPI (Bundesverband der Pharmazeutischen Industrie e.V.)minorOthersFederation of the Pharmaceutical Industry representing research-oriented cannabis manufacturers. Represents pharmaceutical industry on national and international levels with over 270 member companies.
• EUMCA (European Medical Cannabis Association)minorOthersAuthoritative voice of the medical cannabis industry representing European manufacturers and suppliers of pharmaceutical-grade cannabis products.

Scale indicators7 records

Recent moves13 records

Expansion highlights7 records

Broad incumbents

• Stada Arzneimittel: Major German generic and specialty pharmaceutical company with a growing cannabis portfolio. Provides a large-incumbent reference point for how established pharma competes with focused players like Avextra in German pharmacy channels.
• Canopy Growth: Large diversified cannabis operator with EU GMP production and German distribution; already an Avextra distribution partner in some regions. Competes broadly in medical cannabis across Europe while also serving consumer markets.

Direct peers

• Columbia Care: U.S.-listed medical cannabis operator with multi-state and select international operations, focused on pharmaceutical-grade products and clinical research. Comparable to Avextra in standardized, evidence-led cannabis medicines.
• Sanity Group: Berlin-based medical cannabis company operating across cultivation, extraction, and pharmacy distribution in Germany. A direct German-market competitor to Avextra with a similar focus on pharmaceutical-grade products.
• Jazz Pharmaceuticals (GW Pharmaceuticals): Through GW Pharmaceuticals, Jazz markets Sativex and Epidiolex, the most established cannabis-derived prescription medicines globally. Sets the benchmark for evidence-based, regulatory-approved cannabis pharmaceuticals that Avextra is aiming to join in Europe.
• Aurora Cannabis: Canadian medical cannabis producer with significant European distribution, including in Germany. Competes with Avextra in standardized flower and extracts supplied to German pharmacies and wholesalers.
• Clever Leaves: Vertically integrated pharmaceutical cannabis company with EU-GMP certified cultivation and extraction. Notably, Avextra's Head of Drug Development previously served as CEO of Clever Leaves, making it a close operational and strategic comparable.
• Tilray Brands: One of the largest global medical cannabis companies with a strong European footprint, including GMP-certified production and a portfolio of standardized cannabis extracts and capsules. Directly comparable to Avextra in pharmaceutical-grade medical cannabis across Germany and the EU.

Emerging players

• Flora Growth: Vertically integrated cannabis company with pharmaceutical-grade cultivation and EU distribution ambitions. A smaller, earlier-stage peer pursuing similar GMP-certified, clinical-evidence-led positioning as Avextra.

Regional players

• Demecar: German medical cannabis distributor and producer focused primarily on the German market. Comparable as a domestic competitor vying for pharmacy shelf space and physician adoption in Avextra's core geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/avextra-ag

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avextra